No insider purchase over the last 90 days. The latest, by FILLIMITED, was filed 08 Jun 2026.
Who traded when
BuySaleSince the insiders bought
- +16.9%Entry ₩20,100 · Close 06 Nov 2026 ₩23,500
- +6.1%Entry ₩22,150 · Close 06 Nov 2026 ₩23,500
- +55.0%Entry ₩11,850 · Close at T+365 ₩18,370
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- 168,460 sharesKRXDART:20260608000105Canonical exit: 6 Sept 2026 (T+90)
- 160,200 shares0.84% mcap48.7% of flowKRXDART:20260506000443Canonical exit: 27 Jul 2026 (T+90)
- 160,200 shares@ ₩21,168.96380.89% mcap51.3% of flowShareKRXDART:20260506000433Canonical exit: 29 Jul 2026 (T+90)
- 174,396 shares0.97% mcap52.4% of flowKRXDART:20260428000265Canonical exit: 19 Jul 2026 (T+90)
- 195,501 shares0.88% mcap47.6% of flowKRXDART:20260401002128Canonical exit: 15 Jun 2026 (T+90)
- ●Executives0DART
- 164,396 shares0.95% mcap100.0% of flowKRXDART:20260305000589Canonical exit: 17 May 2026 (T+90)
- 803,389 sharesKRXDART:20260202000117Canonical exit: 26 Apr 2026 (T+90)
- ●Executives0DART
- 4,000 sharesShareKRXDART:20241205000411Canonical exit: 5 Mar 2025 (T+90)
- 4,000 sharesKRXDART:20241205000418Canonical exit: 2 Mar 2025 (T+90)
- 160,000 sharesKRXDART:20241128001219Canonical exit: 23 Feb 2025 (T+90)
- 3,215,264 sharesShareKRXDART:20241128001194Canonical exit: 26 Feb 2025 (T+90)
- 3,151,272 sharesKRXDART:20241104000224Canonical exit: 29 Jan 2025 (T+90)
- 500 sharesShareKRXDART:20241104000207Canonical exit: 2 Feb 2025 (T+90)
- 2,000 sharesShareKRXDART:20241104000203Canonical exit: 2 Feb 2025 (T+90)
- 90,000 sharesShareKRXDART:20241104000219Canonical exit: 2 Feb 2025 (T+90)
- 3,508 sharesShareKRXDART:20241104000201Canonical exit: 2 Feb 2025 (T+90)
- 5,508 sharesKRXDART:20240603000243Canonical exit: 27 Aug 2024 (T+90)
- ShareKRXDART:20240603000193Canonical exit: 29 Aug 2024 (T+90)
- ShareKRXDART:20240603000186Canonical exit: 27 Aug 2024 (T+90)
- 5,508 sharesKRXDART:20230427000209Canonical exit: 24 Jul 2023 (T+90)
- 5,508 sharesKRXDART:20230328000316Canonical exit: 26 Jun 2023 (T+90)
25 of 31 declarations
About NeoPharm Co., Ltd.
No sale has been recorded at 네오팜 (NeoPharm Co., Ltd.), and its purchases are sizeable: 5 carry an amount, EUR 9.6 million in all (median EUR 1,945,665). The three largest: EUR 2,140,676 for Fillimited on April 20, 2026, EUR 1,960,153 for 잇츠한불 on April 30, 2026 and EUR 1,945,665 for Fillimited on March 17, 2026.
잇츠한불 files 11, all purchases, and Fillimited (대량보유자) 5. The executive 김양수 (대표이사) has 4 filings, 3 of them purchases, and 임우재 (상무) 2 purchases. From November 4 to December 2, 2024, 5 distinct filers bought. In all, 23 purchases are counted, across 29 filings published between March 10, 2021 and June 8, 2026.
Read moreShow less
South Korean health care at KRW 369.1 billion of capitalisation, 7 filers. The year 2024 has 12 filings and 2026 has 8, against 1, 1, 6 and 1 for 2021, 2022, 2023 and 2025. The stored 90-day median for 21 purchases is 0.2%, with 57% of results positive (recorded past results, not a forecast).
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
